
Journal of Medicinal Chemistry p. 2525 - 2547 (1991)
Update date:2022-09-26
Topics:
Carini, David J.
Duncia, John V.
Aldrich, Paul E.
Chiu, Andrew T.
Johnson, Alexander L.
et al.
A new series of nonpeptide angiotensin II (AII) receptor antagonists has been prepared.These N-(biphenylylmethyl)imidazoles, e.g. 2-butyl-1-<(2'-carboxybiphenyl-4-yl)methyl>-4-chloro-5-(hydroxymethyl)imidazole, differ from the previously reported N-(benzamidobenzyl)imidazoles and related compounds in that they produce a potent antihypertensive effect upon oral administration; the earlier series generally were active only when administered intravenously.It has been found that the acidic group at the 2'-position of the biphenyl is essential.Only ortho-substituted acids possess both high affinity for the AII receptor and good oral antihypertensive potency.The carboxylic acid group has been replaced with a variety of acidic isosteres, and the tetrazole ring has been found to be the most effective.The tetrazole derivative, DuP 753, is currently in development for the treatment of hypertension.
View MoreContact:+36(21)2523420
Address:Head office: 1102 Budapest, SZENT LASZLO TER 24/B. 1/1., HUNGARY / CHINA
Taizhou Chemedir Biopharm-tech Co., Ltd
Contact:+86 523 86200218
Address:G09, No. 1 Avenue China Medical City, Taizhou,Jiangsu, China
Anhui Biochem United Pharmaceutical Co., Ltd.
Contact:0086 551 5167062 / 5228268
Address:No. 30 Hongfeng Road, Hi-Tech Development Zone, Hefei (230088), China
Contact:+86-535-8888888
Address:No.161 Haishi Rd.
SuZhou Ascepion Pharmaceuticals, Inc.(expird)
Contact:0512-86881668
Address:Building C,68Xingqing Road,Suzhou,China.
Doi:10.1016/j.tet.2011.10.043
(2011)Doi:10.1021/ol203041b
(2011)Doi:10.1016/j.dyepig.2011.07.022
(2012)Doi:10.1039/c1cc14463d
(2011)Doi:10.1248/cpb.39.1038
(1991)Doi:10.1039/c1cc15609h
(2011)